Back to results
US 12,130,287 B2Granted
CEACAM1 based point-of-care cancer diagnostic
OwnerGal Markelinventor
Life of this patent
Estimating the term…
Abstract
The present technology regards the utilization of CEACAM1 as a biomarker for cancer. In particular the present invention regards the detection and measurement of soluble CEACAM1 levels for the detection and diagnosis of melanoma.
Claims1
A device for the point-of-care detection of melanoma in a patient, the device configured to detect soluble Carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) level in a biological sample from the patient having melanoma, the device comprising:
- an immunochromatographic strip comprising a sample loading zone,
- a reaction zone having a mobile phase comprising a first CEACAM1 antibody conjugated to a detectable moiety;
- and
- a CEACAM 1 capture zone comprising an immobilized CEACAM1 binding agent;
- wherein said first CEACAM1 antibody binds to the CEACAM1 A2 domain, and said immobilized CEACAM1 binding agent is a member the CEA protein family;
- and
- wherein a detectable signal accumulates in the capture zone when the biological sample comprises at least 30 ng/ml soluble CECAM1.
4 more elements
Dependencies are inferred from the claim text.